University of Montana
Erica L. Woodahl, Ph.D. is an Associate Professor at the University of Montana in the Department of Biomedical and Pharmaceutical Sciences. Erica Woodahl received a B.S. in Biochemistry at the University of Notre Dame in 1998 and a Ph.D. from the Department of Pharmaceutics at the University of Washington in 2004. She completed a postdoctoral fellowship in clinical pharmacokinetics at the Fred Hutchinson Cancer Research Center in Seattle, Washington. She joined the faculty at the University of Montana in 2007 as an Assistant Professor and was promoted to Associate Professor in 2012. The research focus of Dr. Woodahl’s laboratory is on precision medicine and pharmacogenomics to identify sources of interindividual variability in disease treatment and prevention (e.g. genes, environment, and lifestyle). We are interested in genetic and environmental factors that alter the pharmacokinetics and pharmacodynamics of many therapeutic compounds. Translation of pharmacogenomics into clinical practice requires genetic research with diverse patient populations to accurately predict drug response and toxicity for all people. Towards this end, we focus on precision medicine and pharmacogenomics with American Indian and Alaska Native populations. Our research is part of the Northwest-Alaska Pharmacogenomics Research Network (NWA-PGRN), whose goals are to engage indigenous populations in precision medicine research. We use community-based participatory research to address complex and important challenges to conducting precision medicine research and aid in the translation of precision medicine research into the clinic. The laboratory is also focused on understanding the mechanisms by which pharmacogenomics alter the function of drug-metabolizing enzymes (e.g. cytochrome P450 drug-metabolizing enzymes), drug transporters (e.g. ATP-binding cassette transporters), and regulatory proteins that contribute to drug disposition. We are using a combination of computational, membrane-based, cell-based, and in vivo models to study the functional consequence of genetic variation in drug-metabolizing enzymes and drug transporters.